Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger

Fineline Cube Jul 15, 2026
Company Deals

Everest Medicines and JD Healthcare Forge Strategic Digital Healthcare Alliance to Accelerate Innovative Drug Access

Fineline Cube Jul 15, 2026
Company Deals

Insilico Medicine and Bora Pharmaceuticals Forge $2.5B Strategic Alliance to Pioneer AI-Driven Drug R&D

Fineline Cube Jul 15, 2026
Company Deals

CR Pharmaceutical Commercial and Innovent Biologics Forge Strategic Partnership to Build Integrated Health Management Ecosystem

Fineline Cube Jul 14, 2026
Company Deals

Dizal Pharmaceutical Secures $1.5 Billion Global Licensing Deal with AstraZeneca for Sunvozertinib in EGFR Exon20ins NSCLC

Fineline Cube Jul 14, 2026
Policy / Regulatory

China’s State Council Unveils “15th Five-Year” National Health Plan with Strong Support for Innovative Therapeutics and AI Integration

Fineline Cube Jul 14, 2026
Company Drug

Innovent Biologics Secures Macau Approval for Dual-Immunotherapy Neoadjuvant Regimen in MSI-H/dMMR Colon Cancer

Fineline Cube Jul 15, 2026
Company Drug

Kelun-Biotech’s Sacituzumab Tirumotecan Achieves World’s First ADC-Immunotherapy Phase III Success in PD-L1-Negative NSCLC

Fineline Cube Jul 15, 2026
Company

Fosun Pharma’s West African Project Nears First-Phase Completion, Aims for 5 Billion Drug Units Annually

Fineline Cube Aug 9, 2024

Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA: 600196; HKG: 2196) has announced the anticipated completion...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gains NMPA Approval for Five Drug Candidates, Including IL-17A mAb for Psoriasis

Fineline Cube Aug 9, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent pharmaceutical company in China, has announced...

Company

Innovent Biologics Reports Over RMB 2 Billion in Q2 2024 Sales, Highlighting 50% YOY Growth

Fineline Cube Aug 9, 2024

Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company in China, has reported a significant...

Company Medical Device

Sansure Biotech’s MTHFR Gene Detection Kit Receives NMPA Approval, Aids in Pregnancy Health Management

Fineline Cube Aug 9, 2024

Sansure Biotech Inc. (SHA: 688289), a specialist in molecular diagnostics based in China, has achieved...

Company Drug

Huadong Medicine Expands Global Footprint with Launch of Aesthetic Injection MaiLi in Singapore

Fineline Cube Aug 9, 2024

Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced the international expansion...

Company Deals

Harbour BioMed Reclaims Rights to HBM7008 as Cullinan Therapeutics Cancels Licensing Deal

Fineline Cube Aug 9, 2024

Harbour BioMed (HBM), a biopharmaceutical company with operations in the Netherlands, the United States, and...

Company Deals R&D

Wondfo Biotech and University of Science, Malaysia Deepen Ties with Formal Partnership

Fineline Cube Aug 9, 2024

Guangzhou Wondfo Biotech Co., Ltd (SHE: 300482), a biotechnology firm based in China, has formalized...

Company Drug

WestGene Biopharma’s EB Virus-Targeting mRNA Vaccine WGc-043 Clears for Clinical Trials in China

Fineline Cube Aug 9, 2024

WestGene Biopharma Co., Ltd., a biotechnology company based in Chengdu, has received approval from the...

Company Deals

Hansoh Pharmaceutical Secures Rights to Lupeng’s BTK Inhibitor LP-168 in Licensing Deal

Fineline Cube Aug 9, 2024

Jiangsu Hansoh Pharmaceutical Co., Ltd (HKG: 3692), a leading pharmaceutical company based in China, has...

Company Drug

Zelgen Biopharmaceuticals’ ZG006 Earns Orphan Drug Designation from FDA for Small-Cell Lung Cancer

Fineline Cube Aug 9, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...

Company

Novo Nordisk Reports 25% YOY Sales Growth in H1 and Q2 2024, Led by GLP-1 Drugs

Fineline Cube Aug 9, 2024

Novo Nordisk (NYSE: NVO), a Danish pharmaceutical giant specializing in diabetes care, has reported its...

Company Legal / IP

Pfizer, Astellas, and University of California Sue Qilu Pharma Over Xtandi Patent Infringement

Fineline Cube Aug 9, 2024

Pfizer Inc. (NYSE: PFE), through its subsidiary Medivation, and co-development partner Astellas Pharma Inc. (TYO:...

Company Deals

WuXi Biologics Partners with Medigene for TCR TCE Development in Refractory Tumors

Fineline Cube Aug 9, 2024

WuXi Biologics (HKG: 2269), a leading Contract Research, Development and Manufacturing Organization (CRDMO) in China,...

Company

Eli Lilly & Co. Resolves Manufacturing Constraints, Reports 37% YOY Sales Growth in Q2 2024

Fineline Cube Aug 9, 2024

Eli Lilly & Co. (NYSE: LLY), a prominent pharmaceutical company based in the U.S., has...

Company Deals

AI-Driven Drug Firms Recursion and Exscientia to Merge in a Deal Valued at Approximately USD 850 Million

Fineline Cube Aug 9, 2024

Recursion (NASDAQ: RXRX), a U.S.-based clinical-stage TechBio company, and Exscientia plc (NASDAQ: EXAI), a U.K.-headquartered...

Company

Viatris Inc. Reports 2% Operational Growth in Q2’24, Driven by Generics and Brands

Fineline Cube Aug 9, 2024

Viatris Inc. has announced its financial results for the second quarter of 2024, highlighting approximately...

Company Drug

Insilico Medicine’s ISM6331 Earns FDA Orphan Drug Designation for Mesothelioma Treatment

Fineline Cube Aug 8, 2024

Insilico Medicine, a China-based biotechnology company at the forefront of generative artificial intelligence (AI), has...

Company

BeiGene’s Q2 2024 Revenues Surge 56% YOY, Highlighted by Strong U.S. Market Performance

Fineline Cube Aug 8, 2024

BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has reported its financial results for the second...

Company

Betta Pharmaceuticals Reports Strong H1 2024 Revenue Growth and Advances in Drug Development

Fineline Cube Aug 8, 2024

Betta Pharmaceuticals Co., Ltd (SHE: 300558), a Chinese pharmaceutical company, has reported its financial results...

Policy / Regulatory

NHSA Preliminary Review Identifies Potential NRDL Additions, Including Novel Therapies and ADCs

Fineline Cube Aug 8, 2024

The National Healthcare Security Administration (NHSA) has released a preliminary list of drugs that have...

Posts pagination

1 … 345 346 347 … 695

Recent updates

  • Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger
  • Everest Medicines and JD Healthcare Forge Strategic Digital Healthcare Alliance to Accelerate Innovative Drug Access
  • Innovent Biologics Secures Macau Approval for Dual-Immunotherapy Neoadjuvant Regimen in MSI-H/dMMR Colon Cancer
  • Kelun-Biotech’s Sacituzumab Tirumotecan Achieves World’s First ADC-Immunotherapy Phase III Success in PD-L1-Negative NSCLC
  • CSPC Pharmaceutical Secures Dual NMPA Breakthrough Therapy Designations for HER2-Positive Breast Cancer Combination
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger

Company Deals

Everest Medicines and JD Healthcare Forge Strategic Digital Healthcare Alliance to Accelerate Innovative Drug Access

Company Drug

Innovent Biologics Secures Macau Approval for Dual-Immunotherapy Neoadjuvant Regimen in MSI-H/dMMR Colon Cancer

Company Drug

Kelun-Biotech’s Sacituzumab Tirumotecan Achieves World’s First ADC-Immunotherapy Phase III Success in PD-L1-Negative NSCLC

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.